Skip to content

Characterization of selenium and glutathione status in critically ill children.

Characterization of selenium and glutathione status in critically ill children.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12616001119482
Enrollment
160
Registered
2016-08-17
Start date
2014-04-04
Completion date
2015-04-08
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Reduced serum selenium concentration is common in adult critically ill patients and correlates to increased morbidity and mortality. Parallel supplementation has in a few studies shown reduced mortality rate and less infectious complications. Pediatric critically ill have not been studied and normal values for Scandinavian pediatric population is not known. Selenium supplementation in premature neonatal have shown less infectious complications. In this study we aim to characterize the normal serum concentration of selenium in healthy children to be commenced for elective surgery (n=60). In parallel pediatric critically ill including newborns (n=100) will be characterized concerning selenium- and glutathione status. This approach might reveal anti-oxidative capacity and mechanisms. Secondary aims are to investigate if the selenium- and glutathione profiles correlate to length of stay and severity of illness (PELOD, PIM2).

Interventions

Serum selenium concentration and glutathione status will be measured at admission and at day 5 in critically ill children and newborns.

Sponsors

Karolinska University Hospital
Lead SponsorHospital

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years
Healthy volunteers
Yes

Inclusion criteria

<18 years of age; BW >1000 grams; expected time in PICU >24 hours

Exclusion criteria

BW <1000 grams; Age >= 18 years; Expected time in PICU <24 hours; moribund patient

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026